{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:28:58Z","timestamp":1787056138944,"version":"build-2736575974"},"reference-count":37,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2026.2964","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:29:38Z","timestamp":1784536178000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Apalutamide\u2011induced prostate\u2011specific antigen response and its association with clinical outcomes in metastatic castration sensitive prostate cancer (Review)"],"prefix":"10.3892","volume":"25","author":[{"given":"Srivatsa","family":"N","sequence":"first","affiliation":[{"name":"Department of Uro\u2011Oncology, Sri Shankara Cancer Hospital and Research Centre, Sri Shankara Cancer Foundation, Affiliated to Rajiv Gandhi University of Health Sciences, Bengaluru, Karnataka 560070, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrakanth","family":"Mv","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hemato\u2011Oncology, Narayana Super Speciality Hospital and Cancer Institute, Affiliated to West Bengal University of Health Sciences, Howrah, West Bengal 711103, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Consultant, Department of Medical Oncology, BIG Apollo Spectra Hospitals, Patna, Bihar 800007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Sonone","sequence":"additional","affiliation":[{"name":"Sun Pharma Laboratories Limited, Mumbai, Maharashtra 400063, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Dharmadhikari","sequence":"additional","affiliation":[{"name":"Sun Pharma Laboratories Limited, Mumbai, Maharashtra 400063, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Puppalwar","sequence":"additional","affiliation":[{"name":"Sun Pharma Laboratories Limited, Mumbai, Maharashtra 400063, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Khandhedia","sequence":"additional","affiliation":[{"name":"Sun Pharma Laboratories Limited, Mumbai, Maharashtra 400063, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey","family":"Mane","sequence":"additional","affiliation":[{"name":"Sun Pharma Laboratories Limited, Mumbai, Maharashtra 400063, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[{"name":"Sun Pharma Laboratories Limited, Mumbai, Maharashtra 400063, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"key20260818144042_b1-MCO-25-3-02964"},{"key":"key20260818144042_b2-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India","volume":"156","author":"Sathishkumar","year":"2022","journal-title":"Indian J Med Res"},{"key":"key20260818144042_b3-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.urolonc.2024.09.028","article-title":"Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter study","volume":"43","author":"Urabe","year":"2025","journal-title":"Urol Oncol"},{"key":"key20260818144042_b4-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.3390\/curroncol29120747","article-title":"Addition of new androgen receptor pathway inhibitors to docetaxel and androgen deprivation therapy in metastatic Hormone-sensitive prostate cancer: A systematic review and metanalysis","volume":"29","author":"Fiorica","year":"2022","journal-title":"Curr Oncol"},{"key":"key20260818144042_b5-MCO-25-3-02964","author":"Schaeffer"},{"key":"key20260818144042_b6-MCO-25-3-02964"},{"key":"key20260818144042_b7-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15545","article-title":"Japanese clinical practice guidelines for prostate cancer 2023","volume":"31","author":"Kohjimoto","year":"2024","journal-title":"Int J Urol"},{"key":"key20260818144042_b8-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"E142","DOI":"10.5489\/cuaj.9240","article-title":"2025 canadian urological Association-canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update)","volume":"19","author":"So","year":"2025","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"key20260818144042_b9-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-1-4","article-title":"Prognostic factors in prostate cancer","volume":"1","author":"Buhmeida","year":"2006","journal-title":"Diagn Pathol"},{"key":"key20260818144042_b10-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.urolonc.2023.03.003","article-title":"Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide","volume":"41","author":"Lowentritt","year":"2023","journal-title":"Urol Oncol"},{"key":"key20260818144042_b11-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"165","DOI":"10.21873\/anticanres.15470","article-title":"The role of fast and deep PSA response in castration-sensitive prostate cancer","volume":"42","author":"Iacovelli","year":"2022","journal-title":"Anticancer Res"},{"issue":"s195","key":"key20260818144042_b12-MCO-25-3-02964","article-title":"Deep prostate-specific antigen response and overall survival in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis","volume":"41 (6_suppl)","author":"Naqvi","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20260818144042_b13-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"501","DOI":"10.6004\/jadpro.2019.10.5.8","article-title":"Apalutamide for the treatment of nonmetastatic Castration-resistant prostate cancer","volume":"10","author":"Patel","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"key20260818144042_b14-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, Castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"key20260818144042_b15-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2217\/fon-2023-0649","article-title":"Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: A plain language summary of the TITAN study","volume":"20","author":"Chowdhury","year":"2024","journal-title":"Future Oncol"},{"issue":"113290","key":"key20260818144042_b16-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113290","article-title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study","volume":"193","author":"Merseburger","year":"2023","journal-title":"Eur J Cancer"},{"key":"key20260818144042_b17-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.prnil.2023.10.003","article-title":"Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study","volume":"12","author":"L\u00f3pez-Abad","year":"2024","journal-title":"Prostate Int"},{"key":"key20260818144042_b18-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jjco\/hyad143","article-title":"Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: A multi-institutional study in the Chu-shikoku Japan Urological Consortium","volume":"54","author":"Tohi","year":"2024","journal-title":"Jap J Clin Oncol"},{"key":"key20260818144042_b19-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","article-title":"Apalutamide in metastatic Castration-sensitive prostate cancer: Results from the multicenter Real-world ARON-3 study","volume":"8","author":"Santoni","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"119","key":"key20260818144042_b20-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030119","article-title":"Multicenter real-world study: 432 patients with apalutamide in metastatic Hormone-sensitive prostate cancer","volume":"32","author":"Encarnaci\u00f3n Navarro","year":"2025","journal-title":"Curr Oncol"},{"issue":"6221","key":"key20260818144042_b21-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206221","article-title":"Ultralow Prostate-specific antigen (PSA) levels and improved oncological outcomes in metastatic Hormone-sensitive prostate cancer (mHSPC) patients treated with apalutamide: A Real-world multicentre study","volume":"13","author":"L\u00f3pez-Abad","year":"2024","journal-title":"J Clin Med"},{"issue":"E387","key":"key20260818144042_b22-MCO-25-3-02964","article-title":"MP29-14 Prostate-specific antigen response and time-to-castration resistance among patients with metastatic castration sensitive prostate cancer initiated on apalutamide, enzalutamide, or abiraterone acetate","volume":"209 (Suppl 4)","author":"Lowentritt","year":"2023","journal-title":"J Urol"},{"issue":"S65","key":"key20260818144042_b23-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00929-6","article-title":"Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)","volume":"42 (Suppl 4)","author":"Maughan","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260818144042_b24-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"key20260818144042_b25-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for Castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20260818144042_b26-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21873\/anticanres.17463","article-title":"Prognostic stratification using early Prostate-specific antigen kinetics in men with metastatic Hormone-sensitive prostate cancer","volume":"45","author":"Hiroshige","year":"2025","journal-title":"Anticancer Res"},{"key":"key20260818144042_b27-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.euo.2020.07.001","article-title":"Patterns of cancer progression of metastatic Hormone-sensitive prostate cancer in the ECOG3805 CHAARTED trial","volume":"3","author":"Bryce","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"s5072","key":"key20260818144042_b28-MCO-25-3-02964","article-title":"Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES","volume":"40 (16_suppl)","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260818144042_b29-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: Post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key20260818144042_b30-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","article-title":"Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals","volume":"23","author":"Collette","year":"2005","journal-title":"J Clin Oncol"},{"issue":"e1334","key":"key20260818144042_b31-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1334","article-title":"Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer","volume":"4","author":"Maeda","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"key20260818144042_b32-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"252.e19","DOI":"10.1016\/j.urolonc.2023.03.013","article-title":"Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study","volume":"41","author":"Lowentritt","year":"2023","journal-title":"Urol Oncol"},{"issue":"e250023","key":"key20260818144042_b33-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0023","article-title":"Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: A head-to-head analysis of real-world patients in the USA","volume":"14","author":"Lowentritt","year":"2025","journal-title":"J Comp Eff Res"},{"issue":"s570","key":"key20260818144042_b34-MCO-25-3-02964","article-title":"Real-world comparison of prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ)","volume":"21 (10_suppl)","author":"Bilen","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"1324181","key":"key20260818144042_b35-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1324181","article-title":"Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A study in the real world","volume":"14","author":"Lu","year":"2024","journal-title":"Front Oncol"},{"issue":"101158","key":"key20260818144042_b36-MCO-25-3-02964","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101158","article-title":"Acetate utilization promotes hormone therapy resistance in prostate cancer through neuroendocrine differentiation","volume":"77","author":"Gao","year":"2024","journal-title":"Drug Resist Updat"},{"key":"key20260818144042_b37-MCO-25-3-02964","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cmet.2022.03.013","article-title":"The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function","volume":"34","author":"Wenes","year":"2022","journal-title":"Cell Metab"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:40:49Z","timestamp":1787053249000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2026.2964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,20]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2026.2964","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}